Julia Mayotte
Nurse Practitioner · Washington, DCNPI 1710744347
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $636 of the $868 with a category attached, or 73.2%. It is spread thinly across 14 manufacturers, the largest accounting for just 22.3%.
Across 21 payments — averaging $41.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$194
- Lilly USA, LLC$157
- Genmab U.S., Inc.$122
- Exelixis Inc.$75
- AbbVie$65
- Incyte Corporation$54
- plus $201 from 8 others
What the payments were for
- Food & beverage$63673%
- Education$23227%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $194 |
| Lilly USA, LLC | 2 | $157 |
| Genmab U.S., Inc. | 1 | $122 |
| Exelixis Inc. | 1 | $75 |
| AbbVie | 2 | $65 |
| Incyte Corporation | 2 | $54 |
| Janssen Scientific Affairs, LLC | 2 | $41 |
| Merck | 2 | $36 |
| Urogen Pharma, Inc. | 1 | $26 |
| Stemline Therapeutics Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$868 in reported general payments places this provider in the 85th percentile of 224 nurse practitioner providers in District of Columbia.
See all nurse practitioner providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValacyclovirValacyclovir Hcl | 11 | $1,004 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Washington
- Rasheda PersingerWashington$88K
- Caitlin YazelWashington$45K
- Aimee LestrangeWashington$37K
- Guinevere QueWashington$27K
- Cynthia BitherWashington$17K
- Safia AbdillahiWashington$11K
- Brigid ReynoldsWashington$6K
- Odette NtamWashington$5K
- Kathryn HilgartnerWashington$5K
- Mary AlderWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.